WuXi AppTec Reports Record First-Half Results in 2022

• Revenue Up 68.5% Year-Over-Year to RMB17,756 Million
• Net Profit Attributable to Owners of the Company Up 73.3% Year-Over-Year to RMB4,636 Million
• Diluted Earnings Per Share (EPS) Up 62.6% Year-Over-Year to RMB1.48
• Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 75.7% Year-Over-Year to RMB4,301 Million
• Adjusted Non-IFRS Diluted EPS Up 73.8% Year-Over-Year to RMB1.46[1]

(SHANGHAI, July 26, 2022) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the first half of the year ending June 30, 2022 (“Reporting Period”).

This release provides a summary of the results and is not intended to be a comprehensive report. For additional information, please refer to the 2022 Interim Report and other relevant announcements published on the websites of the Shanghai Stock Exchange (www.sse.com.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk), and the designated media for dissemination of the relevant information. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.

All financial information disclosed in this press release is prepared based on International Financial Reporting Standards (IFRS), in currency of RMB.

The 2022 First-Half Report of the Company has not been audited.

For the full report & press release, visit: https://prn.to/3OujXeE